ArticleNanomaterials (Basel, Switzerland)2026
Effect of Microfluidization Technique on the Physicochemical Characteristics of Cannabidiol Nanoemulsions.
Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study examines the effect of microfluidization on the physicochemical properties, stability, release behavior, and cytocompatibility of cannabidiol (CBD) nanoemulsions intended for topical application. CBD is a non-psychoactive cannabinoid characterized by anti-inflammatory and analgesic activity; however, its therapeutic use is limited by low solubility and poor bioavailability. To address these limitations, nanoemulsions were formulated using avocado oil and Tween 80 and optimized through a Box-Behnken experimental design evaluating microfluidization pressure (5000-20,000 PSI), CBD concentration (0-2%), and oil content (8-10%). Nanoemulsions were characterized over a 60-day period in terms of droplet size, dispersity index (D), and zeta potential. An increase in processing pressure led to a reduction in both droplet size and dispersity, with optimal conditions identified between 11,000 and 15,000 PSI. Higher oil and CBD concentrations were associated with an increase in the magnitude of the zeta potential, contributing to electrostatic stabilization of the system. Encapsulation efficiency reached approximately 81.4%. Cell viability assays in HaCaT keratinocytes indicated no significant cytotoxic effects. The optimized formulation exhibited a sigmoidal CBD release profile best described by Weibull and Gompertz models (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.